Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) EBT Margin: 2020-2025

Historic EBT Margin for Relay Therapeutics (RLAY) over the last 3 years, with Jun 2025 value amounting to -10,301.62%.

  • Relay Therapeutics' EBT Margin was N/A to -10,301.62% in Q2 2025 from the same period last year, while for Jun 2025 it was -1,693.16%, marking a year-over-year change of. This contributed to the annual value of -3,374.86% for FY2024, which is 203627.00% down from last year.
  • As of Q2 2025, Relay Therapeutics' EBT Margin stood at -10,301.62%, which was down 926.61% from -1,003.46% recorded in Q1 2025.
  • Over the past 5 years, Relay Therapeutics' EBT Margin peaked at 8,349,600.00% during Q4 2023, and registered a low of -82,765.55% during Q2 2023.
  • Moreover, its 3-year median value for EBT Margin was -1,003.46% (2025), whereas its average is 1,173,250.90%.
  • Per our database at Business Quant, Relay Therapeutics' EBT Margin crashed by 73,069,408bps in 2021 and then skyrocketed by 837,627,154bps in 2023.
  • Relay Therapeutics' EBT Margin (Quarterly) stood at -11,897.00% in 2021, then tumbled by 1,477,454bps to -26,671.54% in 2022, then skyrocketed by 837,627,154bps to 8,349,600.00% in 2023, then soared by 4,088,512bps to -813.55% in 2024, then slumped by 18,991bps to -10,301.62% in 2025.
  • Its EBT Margin stands at -10,301.62% for Q2 2025, versus -1,003.46% for Q1 2025 and -813.55% for Q1 2024.